#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Arginase deficiency Prolymphocytic leukaemia Oesophageal adenocarcinoma stage III Peritoneal neoplasm Cluster headache White matter lesion Inflammatory myofibroblastic tumour Renal cancer metastatic Small intestine adenocarcinoma Astrocytoma malignant Osteomyelitis Thalassaemia Pouchitis Isodicentric chromosome 15 syndrome Glioma More trials…

    Learn about Rare Diseases

    Focal segmental glomerulosclerosis – Treatment Fabry’s disease – Treatment Leiomyosarcoma metastatic – Trials in Disease Mucopolysaccharidosis III – Treatment Ewing’s sarcoma recurrent – Basic Information X-linked lymphoproliferative syndrome – Life with Disease Osteosarcoma recurrent – Diagnostics Mantle cell lymphoma refractory – Trials in Disease KBG syndrome Haemophilia A without inhibitors More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Asundexian Sodium Gluconate Volrustomig Nedosiran ULVIPRUBART Alks 2680 Azetukalner Furosemide Ph. Eur. Tremelimumab Quemliclustat Ads-013 Exl01 Alxn2220 Mepivacaine Hydrochloride Lisinopril Dihydrate Perampanel Hydroxypropyl Cellulose Lf Timrepigene Emparvovec Isoleucine Cimetidine More therapies…

    Learn about Your Condition

    Immunodeficiency Neoplasm Testicular leiomyosarcoma Alcoholic liver disease Macular degeneration Seizure Brain neoplasm Portal hypertension Gastric cancer stage IV Hypervolaemia Pulmonary hypertension Intracranial calcification Papillary thyroid cancer Systemic candida Pneumonia chlamydial More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chemotherapy cardiotoxicity attenuation

  • Early detection of heart damage using cardiac magnetic resonance imaging in cancer patients receiving doxorubicin, epirubicin, pixantrone and other anthracyclines

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chemotherapy cardiotoxicity attenuation
    Investigated Drugs:
    • Mitoxantrone Hydrochloride
    • Daunorubicin Hydrochloride
    • Epirubicin Hydrochloride
    Germany

  • Study on Empagliflozin to Prevent Heart Damage in Cancer Patients Receiving Anthracycline Chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Chemotherapy cardiotoxicity attenuation
    Investigated Drugs:
    • Empagliflozin
    Poland

  • Study on Dapagliflozin to Reduce Heart Damage from Chemotherapy in Breast Cancer Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chemotherapy cardiotoxicity attenuation
    Investigated Drugs:
    • Dapagliflozin
    Italy

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!